Salvatore Siena
Salvatore Siena
Università degli Studi di Milano, Niguarda Cancer Center, Grande Ospedale Metropolitano Niguarda
Підтверджена електронна адреса в - Домашня сторінка
Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer
D Cunningham, Y Humblet, S Siena, D Khayat, H Bleiberg, A Santoro, ...
New England journal of medicine 351 (4), 337-345, 2004
Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer
RG Amado, M Wolf, M Peeters, E Van Cutsem, S Siena, DJ Freeman, ...
Detection of circulating tumor DNA in early-and late-stage human malignancies
C Bettegowda, M Sausen, RJ Leary, I Kinde, Y Wang, N Agrawal, ...
Science translational medicine 6 (224), 224ra24-224ra24, 2014
Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer
E Van Cutsem, M Peeters, S Siena, Y Humblet, A Hendlisz, B Neyns, ...
Journal of clinical oncology 25 (13), 1658-1664, 2007
Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective …
W De Roock, B Claes, D Bernasconi, J De Schutter, B Biesmans, ...
The lancet oncology 11 (8), 753-762, 2010
Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial
A Grothey, E Van Cutsem, A Sobrero, S Siena, A Falcone, M Ychou, ...
The Lancet 381 (9863), 303-312, 2013
Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer
F Di Nicolantonio, M Martini, F Molinari, A Sartore Bianchi, S Arena, ...
Panitumumab–FOLFOX4 treatment and RAS mutations in colorectal cancer
JY Douillard, KS Oliner, S Siena, J Tabernero, R Burkes, M Barugel, ...
New England Journal of Medicine 369 (11), 1023-1034, 2013
Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with …
JY Douillard, S Siena, J Cassidy, J Tabernero, R Burkes, M Barugel, ...
Journal of clinical oncology 28 (31), 4697-4705, 2010
Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer
S Misale, R Yaeger, S Hobor, E Scala, M Janakiraman, D Liska, E Valtorta, ...
Nature 486 (7404), 532-536, 2012
Gene copy number for epidermal growth factor receptor (EGFR) and clinical response to antiEGFR treatment in colorectal cancer: a cohort study
M Moroni, S Veronese, S Benvenuti, G Marrapese, A Sartore-Bianchi, ...
The lancet oncology 6 (5), 279-286, 2005
Oncogenic activation of the RAS/RAF signaling pathway impairs the response of metastatic colorectal cancers to anti–epidermal growth factor receptor antibody therapies
S Benvenuti, A Sartore-Bianchi, F Di Nicolantonio, C Zanon, M Moroni, ...
Cancer research 67 (6), 2643-2648, 2007
Sorafenib in radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 3 trial
MS Brose, CM Nutting, B Jarzab, R Elisei, S Siena, L Bastholt, ...
The Lancet 384 (9940), 319-328, 2014
Granulocyte-macrophage colony-stimulating factor to harvest circulating haemopoietic stem cells for autotransplantation
AM Gianni, S Siena, M Bregni, AC Stern, C Tarella, A Pileri, G Bonadonna
The Lancet 334 (8663), 580-585, 1989
PIK3CA mutations in colorectal cancer are associated with clinical resistance to EGFR-targeted monoclonal antibodies
A Sartore-Bianchi, M Martini, F Molinari, S Veronese, M Nichelatti, ...
Cancer research 69 (5), 1851-1857, 2009
Association of KRAS p. G13D mutation with outcome in patients with chemotherapy-refractory metastatic colorectal cancer treated with cetuximab
W De Roock, DJ Jonker, F Di Nicolantonio, A Sartore-Bianchi, D Tu, ...
Jama 304 (16), 1812-1820, 2010
Integrating liquid biopsies into the management of cancer
G Siravegna, S Marsoni, S Siena, A Bardelli
Nature reviews Clinical oncology 14 (9), 531-548, 2017
Molecular mechanisms of resistance to cetuximab and panitumumab in colorectal cancer
A Bardelli, S Siena
Journal of clinical oncology 28 (7), 1254-1261, 2010
A molecularly annotated platform of patient-derived xenografts (“xenopatients”) identifies HER2 as an effective therapeutic target in cetuximab-resistant colorectal cancer
A Bertotti, G Migliardi, F Galimi, F Sassi, D Torti, C Isella, D Corà, ...
Cancer discovery 1 (6), 508-523, 2011
Flow cytometry for clinical estimation of circulating hematopoietic progenitors for autologous transplantation in cancer patients
S Siena, M Bregni, B Brando, N Belli, F Ravagnani, L Gandola, AC Stern, ...
У даний момент система не може виконати операцію. Спробуйте пізніше.
Статті 1–20